Yazar "Genc, Ahmet" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Effect of Bendopnea on Achievement Medical Treatment Target Doses in Heart Failure
    (Acad Medical Sciences I R Iran, 2023) Oztekin, Gulsum Meral Yilmaz; Genc, Ahmet; Sahin, Anil; Cagirci, Goeksel; Arslan, Sakir
    Background: The newly described bendopnea in heart failure (HF) is associated with increased cardiac filling pressures. The aim of the study was to show the effect of bendopnea follow-up on reaching optimal medical treatment doses in HF. Methods: A total of 413 patients were screened, and we included 203 patients with HF who were previously evaluated for bendopnea. Demographic data, presence or absence of bendopnea, medical history, laboratory findings, and medical treatments were evaluated. Optimal medical therapy target doses at baseline and 3rd month were compared in groups with and without bendopnea. Results: On admission, 64 patients (31.5%) had bendopnea. The rate of patients with bendopnea decreased in the 3rd month (n = 42, 20.7%). The proportion of patients who used at least 50% of the recommended medical treatment dose on admission and in the 3rd month was compared; angiotensin-converting enzyme inhibitor /angiotensin receptor blockers use increased from 40.6% to 71.9% in those with bendopnea (P = 0.013), from 56.1% to 81.3% in those without bendopnea (P < 0.001) and beta-blockers use increased from 28.2% to 60.9% in those with bendopnea (P = 0.042), from 31.6% to 69.8% in those without bendopnea (P < 0.001). However, aldosterone antagonists use decreased from 70.3% to 67.2% in those with bendopnea (P = 0.961), from 68.4 % to 64.1% in those without bendopnea (P = 0.334). Bendopnea was independently effective in achieving ACE-I/ARB target doses (OR: 0.359, CI 95%: 0.151-0.854, P = 0.020). Conclusion: Bendopnea follow-up in HF patients can provide a significant improvement in reaching the recommended treatment target doses.
  • Küçük Resim Yok
    Öğe
    Effects of the perimenopausal period on the course of heart failure
    (Cukurova Univ, Fac Medicine, 2023) Sahin, Emine Tugce; Oztekin, Gulsum Meral Yilmaz; Genc, Ahmet; Sahin, Anil; Ozen, Mehmet
    Purpose: It is known that the decrease in estrogen level in women's life has negative effects on the cardiovascular system. In this study, it was aimed to elucidate the changes in the clinical status and treatment requirement of patients with heart failure (HF) during the menopausal transition period.Materials and Methods: A total of 26 patients followed up in the HF outpatient clinic between 2015-2020 were included in this retrospective, single-center study. Demographic data of the patients, New York Heart Association class, echocardiographic findings, routine biochemical parameters and HF signs, symptoms and therapies were examined. Data at the beginning of the menopause period and after 12 months were compared.Results: At the end of the 12-month follow-up, a statistically significant increase was found in the daily dose of furosemide (50.5 mg/day vs. 72.4 mg/day). While the mean heart rate of the patients was 80.4 +/- 20.1 beats/min at the beginning, it was 69.3 +/- 10.1 beats/min in the control visit. Echocardiographically measured left ventricular (LV) systolic diameters of the patients were significantly increased compared to baseline in the control visit (41.2 +/- 7.4 mm vs 45.8 +/- 7.0 mm,).Conclusion: The menopausal period caused an increase in the need for treatment in patients followed up with HF. Therefore, in evaluation of the patients with HF, it would be a useful approach to question the menopausal status in detail and to follow the patients more closely during the menopausal transition period.